Amicus Therapeutics Inc., of Cranbury, N.J., said Galafold (migalastat), the first oral treatment option for people living with Fabry disease, and who have an amenable variant, grew in revenue from $91.2 million in full-year 2018 to $182.2 million in full-year 2019, exceeding the high end of the full-year 2019 guidance range of $170 million to $180 million. Over the course of 2019, Amicus gained marketing authorizations for the product around the globe, including Argentina, Brazil, Colombia and Taiwan. For the full-year 2020, Amicus anticipates total Galafold revenue of $250 million to $260 million based on the average exchange rates for 2019. The company posted a net loss of $356.4 million, or $1.48 per share, for the year. As of Dec. 31, cash, equivalents and marketable securities totaled $452.7 million. Shares of Amicus (NASDAQ:FOLD) closed March 2 at $9.32, down 23 cents.